CARE N CARE HEALTH PLAN

Similar documents
CARE N CARE HEALTH PLAN

ARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.

HEALTHTEAM ADVANTAGE PLAN 2017 Step Therapy Criteria Pending CMS Approval

CARE N CARE HEALTH PLAN

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

HEALTHTEAM ADVANTAGE 2018 Step Therapy Criteria

PPHP 2017 Formulary 2017 Step Therapy Criteria

BRINTELLIX. Step Therapy Criteria HealthTeam Advantage Formulary ID: Version 6 Effective Date: 1/1/2016. PRODUCT(s) AFFECTED BRINTELLIX

DIFICID. Products Affected Step 2: DIFICID TABLET 200 MG ORAL. Details

ANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017

ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR

Step Therapy Group. Atypical Antipsychotic Agents

Drug Name (specify drug) Quantity Frequency Strength

These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details.

2016 Step Therapy (ST) Criteria

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Step Therapy Requirements. Effective: 1/1/2019

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

RHEUMATOID ARTHRITIS DRUGS

Drug Therapy Guidelines

ACYCLOVIR OINT (CCHP2017)

Simponi / Simponi ARIA (golimumab)

ACYCLOVIR OINT (CCHP2017)

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

**CRITERIA UNDER CMS REVIEW**

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

Step Therapy Criteria

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria

ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019

Step Therapy Medications

2019 Simply Step Therapy Document

Step Therapy Requirements. Effective: 05/01/2018

Regulatory Status FDA approved indication: Kineret is an interleukin-1 receptor antagonist indicated for: (1)

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

ALLERGIC CONJUNCTIVITIS AGENTS

Step Therapy Requirements. Effective: 11/01/2018

2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:

Pharmacy Management Drug Policy

Otezla. Otezla (apremilast) Description

Cimzia. Cimzia (certolizumab pegol) Description

DRAFT. Therapeutic Class Code: D6A, S2J, S2M, S2Q, Z2U, Z2Z, S2Z, L1A, S2V, Z2V, D6K Therapeutic Class Description: Injectable Immunomodulators

Cimzia. Cimzia (certolizumab pegol) Description

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

ANTIDIABETIC AGENTS - MISCELLANEOUS

Memorial Hermann Advantage HMO February 2019 Formulary Addendum

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Simply Step Therapy Document September 2018 Y0114_18_33074_I_009

ANTIDIABETIC AGENTS - MISCELLANEOUS

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Step Therapy Criteria 2019

ANTIDIABETIC AGENTS - MISCELLANEOUS

March 2017 Pharmacy & Therapeutics Committee Decisions

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

2019 PDP Basic Step Therapy Document

2017 Step Therapy Criteria

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

ACYCLOVIR OINT (CCHP2017)

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

Cimzia. Cimzia (certolizumab pegol) Description

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65

2018 Step Therapy (ST) Criteria

Cosentyx. Cosentyx (secukinumab) Description

Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017

ACTEMRA (tocilizumab)

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

CYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID

The Medical Letter. on Drugs and Therapeutics

STEP THERAPY CRITERIA

Stelara. Stelara (ustekinumab) Description

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

Biologics for Autoimmune Diseases

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

ANTICONVULSANTS. Details

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

ANTICONVULSANTS. Details

ATYPICAL ANTIPSYCHOTICS

5-ASA. Products Affected. Details. Dipentum 250 mg capsule. Lialda 1.2 gram tablet,delayed release

Rexulti (brexpiprazole)

NB Drug Plans Formulary Update

Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria

Transcription:

ARISTADA Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882 MG/3.2ML Intramuscular Claim will pay automatically for ARISTADA if enrollee has a paid claim for at least a 1 days supply of oral aripiprazole or ABILIFY MAINTENA AND LATUDA in the past. Otherwise, ARISTADA requires a step therapy exception request indicating: (1) history of inadequate treatment response with oral aripiprazole or ABILIFY MAINTENA AND LATUDA, OR (2) oral aripiprazole was previously tolerated but there is a history of adverse event with ABILIFY MAINTENA and LATUDA, OR (3) oral aripiprazole was previously tolerated but ABILIFY MAINTENA and LATUDA are contraindicated. 1

MYRBETRIQ Myrbetriq Tablet Extended Release 24 Hour 25 MG Oral Myrbetriq Tablet Extended Release 24 Hour 50 MG Oral Claim will pay automatically for Myrbetriq if enrollee has a paid claim for at least a 1 days supply of any formulary urinary anticholinergic in the past. Otherwise, Myrbetriq requires a step therapy exception request indicating: (1) history of inadequate treatment response with formulary urinary anticholinergic, OR (2) history of adverse event with formulary urinary anticholinergic, OR (3) formulary urinary anticholinergic is contraindicated. 2

PANCREATIC ENZYMES Creon CAPSULE DELAYED RELEASE PARTICLES 12000 UNIT ORAL Creon CAPSULE DELAYED RELEASE PARTICLES 24000 UNIT ORAL Creon CAPSULE DELAYED RELEASE PARTICLES 3000-9500 UNIT ORAL Creon CAPSULE DELAYED RELEASE PARTICLES 36000 UNIT ORAL Creon CAPSULE DELAYED RELEASE PARTICLES 6000 UNIT ORAL Pertzye CAPSULE DELAYED RELEASE PARTICLES 16000 UNIT ORAL Pertzye CAPSULE DELAYED RELEASE PARTICLES 4000 UNIT ORAL Pertzye CAPSULE DELAYED RELEASE PARTICLES 8000 UNIT ORAL 1. The patient is currently stabilized on Creon or Pertzye, OR 2. The patient has had a trial of Zenpep or Pancreaze OR 3. The patient has had an inadequate response after a trial of Zenpep or Pancreaze OR 4. The patient is intolerant to or had an adverse reaction with Zenpep or Pancreaze. 3

PPI Dexilant CAPSULE DELAYED RELEASE 30 MG ORAL Dexilant CAPSULE DELAYED RELEASE 60 MG ORAL Claim will pay automatically for Dexilant if enrollee has a paid claim for at least a 1 days supply of lansoprazole, omeprazole, pantoprazole, or rabeprazole in the past. Otherwise, Dexilant requires a step therapy exception request indicating: (1) history of inadequate treatment response with lansoprazole, omeprazole, pantoprazole, or rabeprazole, OR (2) history of adverse event with lansoprazole, omeprazole, pantoprazole, or rabeprazole, OR (3) lansoprazole, omeprazole, pantoprazole, or rabeprazole is contraindicated. 4

RHEUMATOID ARTHRITIS Actemra SOLUTION 200 MG/10ML Intravenous Actemra SOLUTION 400 MG/20ML Intravenous Actemra SOLUTION 80 MG/4ML Intravenous Actemra Solution Prefilled Syringe 162 MG/0.9ML Subcutaneous Cimzia KIT 2 X 200 MG Subcutaneous Cimzia Prefilled KIT 2 X 200 MG/ML Subcutaneous Cosentyx Sensoready Pen Solution Auto-injector 150 MG/ML Subcutaneous Cosentyx Solution Prefilled Syringe 150 MG/ML Subcutaneous Kineret Solution Prefilled Syringe 100 MG/0.67ML Subcutaneous Orencia ClickJect Solution Auto-injector 125 MG/ML Subcutaneous Orencia Solution Prefilled Syringe 125 MG/ML Subcutaneous Orencia SOLUTION RECONSTITUTED 250 MG Intravenous Simponi Aria SOLUTION 50 MG/4ML Intravenous Simponi Solution Auto-injector 100 MG/ML Subcutaneous Simponi Solution Auto-injector 50 MG/0.5ML Subcutaneous Simponi Solution Prefilled Syringe 100 MG/ML Subcutaneous Simponi Solution Prefilled Syringe 50 MG/0.5ML Subcutaneous Stelara SOLUTION 130 MG/26ML Intravenous Stelara Solution Prefilled Syringe 45 MG/0.5ML Subcutaneous Stelara Solution Prefilled Syringe 90 MG/ML Subcutaneous Xeljanz TABLET 5 MG ORAL Claim will pay automatically for Actrema, Cimzia, Cosentyx, Kineret, Orencia, Simponi, Stelara, or Xeljanz if enrollee has a paid claim for at least a 1 days supply of Enbrel or Humira in the past. Otherwise, Actrema, Cimzia, Cosentyx, Kineret, Orencia, Simponi, Stelara, or Xeljanz requires a step therapy exception request indicating: (1) history of inadequate treatment response with Enbrel or Humira, OR (2) history of adverse event with Enbrel or Humira, OR (3) Enbrel or Humira is contraindicated, OR (4) For diagnosis cryopyrin-associated periodic syndromes, Kineret will be approved. 5

TRINTELLIX Trintellix TABLET 10 MG ORAL Trintellix TABLET 20 MG ORAL Trintellix TABLET 5 MG ORAL Claim will pay automatically for trintellix if enrollee has a paid claim for at least a 1 days supply of any 2 generic formulary antidepressants in the past. Otherwise, trintellix requires a step therapy exception request indicating: (1) history of inadequate treatment response with any 2 generic formulary antidepressants, OR (2) history of adverse event with any 2 generic formulary antidepressantss, OR (3) any 2 generic formulary antidepressants are contraindicated. 6

UCERIS Uceris FOAM 2 MG/ACT Rectal Uceris Tablet Extended Release 24 Hour 9 MG Oral Claim will pay automatically for Uceris if enrollee has a paid claim for at least a 1 days supply of any formulary corticosteroid used to treat ulcerative colitis in the past. Otherwise, Uceris requires a step therapy exception request indicating: (1) history of inadequate treatment response with formulary corticosteroid used to treat ulcerative colitis, OR (2) history of adverse event with formulary corticosteroid used to treat ulcerative colitis, OR (3) formulary corticosteroid used to treat ulcerative colitis is contraindicated. 7

VRAYLAR Vraylar CAPSULE 1.5 MG Oral Vraylar CAPSULE 3 MG Oral Vraylar CAPSULE 4.5 MG ORAL Vraylar CAPSULE 6 MG ORAL Vraylar Capsule Therapy Pack 1.5 & 3 MG Oral Claim will pay automatically for VRAYLAR if enrollee has a paid claim for at least a 1 days supply of ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, QUITIAPINE ER, RISPERIDONE, ZIPRASIDONE OR LATUDA in the past 365 days. Otherwise, Vraylar requires a step therapy exception request indicating any ONE of criteria 1,2,3, OR 4: (1) history of inadequate treatment response with ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, QUITIAPINE ER, RISPERIDONE, ZIPRASIDONE, or LATUDA OR (2) history of adverse event with ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, QUITIAPINE ER, RISPERIDONE, ZIPRASIDONE, or LATUDA OR (3) ARIPIPRAZOLE, OLANZAPINE, QUETIAPINE, QUITIAPINE ER, RISPERIDONE, ZIPRASIDONE or LATUDA are contraindicated. OR (4) FOR Diagnosis OF MANIC EPIPISODES ASSOCIATED WTIH BIPOLAR DISORDER, THE COVERAGE DETERMINATION WILL BE APPROVED WITHOUT REQUIREMENT OF TRIAL AND FAILURE OR CONTRAINDICATION TO LATUDA. 8

XTANDI Xtandi CAPSULE 40 MG ORAL Claim will pay automatically for Xtandi if enrollee has a paid claim for at least a 1 days supply of Zytiga in the past. Otherwise, Xtandi requires a step therapy exception request indicating: (1) history of inadequate treatment response with Zytiga, OR (2) history of adverse event with Zytiga, OR (3) Zytiga is contraindicated. 9

Alphabetical Listing A Actemra SOLUTION 200 MG/10ML Intravenous... 5 Actemra SOLUTION 400 MG/20ML Intravenous... 5 Actemra SOLUTION 80 MG/4ML Intravenous... 5 Actemra Solution Prefilled Syringe 162 MG/0.9ML Subcutaneous... 5 Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular... 1 Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular... 1 Aristada Prefilled Syringe 882 MG/3.2ML Intramuscular... 1 C Cimzia KIT 2 X 200 MG Subcutaneous... 5 Cimzia Prefilled KIT 2 X 200 MG/ML Subcutaneous... 5 Cosentyx Sensoready Pen Solution Autoinjector 150 MG/ML Subcutaneous... 5 Cosentyx Solution Prefilled Syringe 150 MG/ML Subcutaneous... 5 Creon CAPSULE DELAYED RELEASE PARTICLES 12000 UNIT ORAL... 3 Creon CAPSULE DELAYED RELEASE PARTICLES 24000 UNIT ORAL... 3 Creon CAPSULE DELAYED RELEASE PARTICLES 3000-9500 UNIT ORAL.. 3 Creon CAPSULE DELAYED RELEASE PARTICLES 36000 UNIT ORAL... 3 Creon CAPSULE DELAYED RELEASE PARTICLES 6000 UNIT ORAL... 3 D Dexilant CAPSULE DELAYED RELEASE 30 MG ORAL... 4 Dexilant CAPSULE DELAYED RELEASE 60 MG ORAL... 4 K Kineret Solution Prefilled Syringe 100 MG/0.67ML Subcutaneous... 5 M Myrbetriq Tablet Extended Release 24 Hour 25 MG Oral... 2 Myrbetriq Tablet Extended Release 24 Hour 50 MG Oral... 2 O Orencia ClickJect Solution Auto-injector 125 MG/ML Subcutaneous... 5 Orencia Solution Prefilled Syringe 125 MG/ML Subcutaneous... 5 Orencia SOLUTION RECONSTITUTED 250 MG Intravenous... 5 P Pertzye CAPSULE DELAYED RELEASE PARTICLES 16000 UNIT ORAL... 3 Pertzye CAPSULE DELAYED RELEASE PARTICLES 4000 UNIT ORAL... 3 Pertzye CAPSULE DELAYED RELEASE PARTICLES 8000 UNIT ORAL... 3 S Simponi Aria SOLUTION 50 MG/4ML Intravenous... 5 Simponi Solution Auto-injector 100 MG/ML Subcutaneous... 5 Simponi Solution Auto-injector 50 MG/0.5ML Subcutaneous... 5 Simponi Solution Prefilled Syringe 100 MG/ML Subcutaneous... 5 Simponi Solution Prefilled Syringe 50 MG/0.5ML Subcutaneous... 5 Stelara SOLUTION 130 MG/26ML Intravenous... 5 Stelara Solution Prefilled Syringe 45 MG/0.5ML Subcutaneous... 5 Stelara Solution Prefilled Syringe 90 MG/ML Subcutaneous... 5 T Trintellix TABLET 10 MG ORAL... 6 Trintellix TABLET 20 MG ORAL... 6 Trintellix TABLET 5 MG ORAL... 6 U Uceris FOAM 2 MG/ACT Rectal... 7 10

Uceris Tablet Extended Release 24 Hour 9 MG Oral... 7 V Vraylar CAPSULE 1.5 MG Oral... 8 Vraylar CAPSULE 3 MG Oral... 8 Vraylar CAPSULE 4.5 MG ORAL... 8 Vraylar CAPSULE 6 MG ORAL... 8 Vraylar Capsule Therapy Pack 1.5 & 3 MG Oral... 8 X Xeljanz TABLET 5 MG ORAL... 5 Xtandi CAPSULE 40 MG ORAL... 9 11